Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase II Study of Metronomic Chemotherapy [Cyclophosphamide + methotrexate + prednisolone] Plus the Same Aromatase Inhibitor [anastrozole, exemestane, letrozole] Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 [human epidermal growth factor receptor 2] Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF [vascular endothelial growth factor] and VEGFR [vascular endothelial growth factor receptor]

Next Previous
Trial Profile

Randomised Phase II Study of Metronomic Chemotherapy [Cyclophosphamide + methotrexate + prednisolone] Plus the Same Aromatase Inhibitor [anastrozole, exemestane, letrozole] Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 [human epidermal growth factor receptor 2] Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF [vascular endothelial growth factor] and VEGFR [vascular endothelial growth factor receptor]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole; Aromatase inhibitors; Cyclophosphamide; Exemestane; Letrozole; Methotrexate; Prednisolone
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jun 2010 Thirteen patients have been accured to date, according to information reported at ASCO 2010
  • 17 Jun 2009 Biomarkers information updated
  • 22 Jun 2008 Status change from initiated to recruiting according to clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top